Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

Next Previous
Search
Trial Profile

An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

Status: Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 03 Feb 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asfotase alfa (Primary) ; Bortezomib (Primary) ; Bortezomib (Primary) ; Folic acid (Primary) ; Methotrexate (Primary) ; Methotrexate (Primary) ; Rituximab (Primary)
  • Indications Hypophosphatasia
  • Focus Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Alexion AstraZeneca Rare Disease

    • Most Recent Events

    • 29 Jan 2025 Planned End Date changed from 15 Jan 2029 to 14 Feb 2029.
    • 29 Jan 2025 Planned primary completion date changed from 15 Jan 2029 to 14 Feb 2029.
    • 29 Jan 2025 Planned initiation date changed from 15 Jan 2025 to 2 Jul 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top